COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 2693: Articles 26921-26930  | Next

Estimating the size of the COVID-19 outbreak in Italy: Application of an exponential decay model to the weighted and cumulative average daily growth rate
Bartolomeo, N., Trerotoli, P., Serio, G.
10.1101/2020.05.20.20108241 — Posted: 2020-05-23
Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19
Rhee, S. Y., Lee, J., Nam, H., Kyoung, D.-S., Kim, D. J.
10.1101/2020.05.20.20108555 — Posted: 2020-05-23
Congregate Shelter Characteristics and Prevalence of Asymptomatic SARS-CoV-2
Samuels, E. A., Karb, R., Vanjani, R., Trimbur, M. C., Napoli, A.
10.1101/2020.05.21.20108985 — Posted: 2020-05-23
Validation of the Kuwait Progression Indicator Score for predicting progression of severity in COVID19
Al Youha, S., Doi, S. A., Jamal, M. H., Almazeedi, S., Al Haddad, M., AlSeaidan, M., Al-Muhaini, A. Y., Al-Ghimlas, F., Al-Sabah, S. K.
10.1101/2020.05.21.20108639 — Posted: 2020-05-23
Effective Screening of SARS-CoV-2 Neutralizing Antibodies in Patient Serum using Lentivirus Particles Pseudotyped with SARS-CoV-2 Spike Glycoprotein
Tandon, R., Mitra, D., Sharma, P., Stray, S. J., Bates, J. T., Marshall, G. D.
10.1101/2020.05.21.20108951 — Posted: 2020-05-23
What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate, serial interval, and asymptomatic infection
Koh, W. C., Naing, L., Rosledzana, M. A., Alikhan, M. F., Chaw, L., Griffith, M., Pastore, R., Wong, J.
10.1101/2020.05.21.20108746 — Posted: 2020-05-23
Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review
Weiss, A., Jellingsoe, M., Sommer, M. O. A.
10.1101/2020.05.21.20108605 — Posted: 2020-05-23
The estimations of the COVID-19 incubation period: a systematic review of the literature
Zaki, N., Mohamed, E. A.
10.1101/2020.05.20.20108340 — Posted: 2020-05-23
Immunity after COVID-19: protection or sensitization ?
Danchin, A., TURINICI, G.
10.1101/2020.05.21.20108860 — Posted: 2020-05-23
Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens
Bravi, F., Flacco, M. E., Carradori, T., Volta, C. A., Cosenza, G., De Togni, A., Acuti Martellucci, C., Parruti, G., Mantovani, L., Manzoli, L.
10.1101/2020.05.21.20109082 — Posted: 2020-05-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).